[go: up one dir, main page]

WO1999013920A3 - Methode pour le traitement curatif des affections proliferatives - Google Patents

Methode pour le traitement curatif des affections proliferatives Download PDF

Info

Publication number
WO1999013920A3
WO1999013920A3 PCT/EP1998/005741 EP9805741W WO9913920A3 WO 1999013920 A3 WO1999013920 A3 WO 1999013920A3 EP 9805741 W EP9805741 W EP 9805741W WO 9913920 A3 WO9913920 A3 WO 9913920A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapy
proliferative diseases
treating proliferative
lesion
site
Prior art date
Application number
PCT/EP1998/005741
Other languages
German (de)
English (en)
Other versions
WO1999013920A2 (fr
Inventor
Ludger Dinkelborg
Christoph-Stephan Hilger
Dieter Heldmann
Friedhelm Blume
Original Assignee
Schering Ag
Ludger Dinkelborg
Hilger Christoph Stephan
Dieter Heldmann
Friedhelm Blume
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19741695A external-priority patent/DE19741695C1/de
Priority claimed from DE1997141694 external-priority patent/DE19741694C2/de
Priority claimed from DE1997142880 external-priority patent/DE19742880A1/de
Application filed by Schering Ag, Ludger Dinkelborg, Hilger Christoph Stephan, Dieter Heldmann, Friedhelm Blume filed Critical Schering Ag
Priority to JP2000511533A priority Critical patent/JP2001516730A/ja
Priority to CA002301887A priority patent/CA2301887A1/fr
Priority to EP98954267A priority patent/EP1011737A2/fr
Priority to AU11459/99A priority patent/AU745908B2/en
Publication of WO1999013920A2 publication Critical patent/WO1999013920A2/fr
Publication of WO1999013920A3 publication Critical patent/WO1999013920A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/38—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode pour le traitement curatif des affections prolifératives, qui est caractérisée en ce qu'un cathéter d'application est tout d'abord placé au niveau du siège de la lésion et en ce qu'une substance radioactive est appliquée localement sur le cathéter, ce dernier est ensuite enlevé et la substance radioactive demeure au niveau du siège de la lésion. L'invention concerne également l'utilisation de dérivés de bisaminoxime, de dérivés complexes de N2S2 et de solutions colloïdales radiomarquées pour la préparation d'agents qui sont appliqués localement lors du traitement des affections prolifératives.
PCT/EP1998/005741 1997-09-18 1998-09-10 Methode pour le traitement curatif des affections proliferatives WO1999013920A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000511533A JP2001516730A (ja) 1997-09-18 1998-09-10 増殖性疾患を治療処置する方法
CA002301887A CA2301887A1 (fr) 1997-09-18 1998-09-10 Methode pour le traitement curatif des affections proliferatives
EP98954267A EP1011737A2 (fr) 1997-09-18 1998-09-10 Methode pour le traitement curatif des affections proliferatives
AU11459/99A AU745908B2 (en) 1997-09-18 1998-09-10 Method for treating proliferative diseases by therapy

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE19741695A DE19741695C1 (de) 1997-09-18 1997-09-18 Verwendung von radioaktiv markierten kolloidalen Lösungen zur Restenoseprophylaxe
DE1997141694 DE19741694C2 (de) 1997-09-18 1997-09-18 Verwendung von Komplexen, deren Ligand ein Bis-Amin-Oxim-Derivat oder ein N¶2¶S¶2¶-Derivat und deren Zentralatom ein Radionuklid ist
DE19742880.0 1997-09-23
DE1997142880 DE19742880A1 (de) 1997-09-23 1997-09-23 Verfahren zur therapeutischen Behandlung proliferativer Erkrankungen
DE19741695.0 1997-09-23
DE19741694.2 1997-09-23

Publications (2)

Publication Number Publication Date
WO1999013920A2 WO1999013920A2 (fr) 1999-03-25
WO1999013920A3 true WO1999013920A3 (fr) 1999-05-06

Family

ID=27217762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/005741 WO1999013920A2 (fr) 1997-09-18 1998-09-10 Methode pour le traitement curatif des affections proliferatives

Country Status (5)

Country Link
EP (1) EP1011737A2 (fr)
JP (1) JP2001516730A (fr)
AU (1) AU745908B2 (fr)
CA (1) CA2301887A1 (fr)
WO (1) WO1999013920A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279502B2 (en) 1999-04-30 2007-10-09 Cellgate, Inc. Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US7312244B2 (en) 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
KR20160037877A (ko) * 2013-06-05 2016-04-06 알-내브, 엘엘씨 Ｔｉｎ―１１７ｍ으로 면역성, 염증성 및 퇴행성 관절염증의 치료 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038730A2 (fr) * 1996-04-17 1997-10-23 Olivier Bertrand Systeme de radiotherapie locale
WO1998012979A1 (fr) * 1996-09-26 1998-04-02 The Trustees Of Columbia University In The City Of New York Procede pour traiter un processus pathologique dans une structure luminale
WO1998030147A1 (fr) * 1997-01-10 1998-07-16 Scimed Life Systems, Inc. Outil et procede permettant d'extraire un dispositif d'un support
WO1998048852A2 (fr) * 1997-04-30 1998-11-05 Schering Aktiengesellschaft Tuteurs a revetement polymere
WO1998048851A2 (fr) * 1997-04-30 1998-11-05 Schering Aktiengesellschaft Tuteurs a revetement radioactif de surface

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038730A2 (fr) * 1996-04-17 1997-10-23 Olivier Bertrand Systeme de radiotherapie locale
WO1998012979A1 (fr) * 1996-09-26 1998-04-02 The Trustees Of Columbia University In The City Of New York Procede pour traiter un processus pathologique dans une structure luminale
WO1998030147A1 (fr) * 1997-01-10 1998-07-16 Scimed Life Systems, Inc. Outil et procede permettant d'extraire un dispositif d'un support
WO1998048852A2 (fr) * 1997-04-30 1998-11-05 Schering Aktiengesellschaft Tuteurs a revetement polymere
WO1998048851A2 (fr) * 1997-04-30 1998-11-05 Schering Aktiengesellschaft Tuteurs a revetement radioactif de surface

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CARDIOVASC. RES. (1989), 23(6), 512-19 CODEN: CVREAU;ISSN: 0008-6363, 1989 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SVENDSEN, JESPER H. ET AL: "Capillary permeability of technetium-99m-DTPA in canine myocardium determined by intracoronary bolus injection and residue detection", XP002095265 *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; AOKI S ET AL: "Supraophthalmic chemotherapy with long tapered catheter: distribution evaluated with intraarterial and intravenous Tc-99m HMPAO.", XP002095232 *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; DELGADO R ET AL: "Renal blood flow distribution during steady-state exercise and exhaustion in conscious dogs.", XP002095233 *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; NAMBA H ET AL: "Assessment of the brain areas perfused by superselective intra-arterial chemotherapy using single photon emission computed tomography with technetium-99m-hexamethyl-propyleneamine oxime--technical note.", XP002095231 *
JOURNAL OF APPLIED PHYSIOLOGY, (1975 SEP) 39 (3) 475-8. JOURNAL CODE: HEF. ISSN: 0021-8987., United States *
NEUROLOGIA MEDICO-CHIRURGICA, (1994 DEC) 34 (12) 832-5. JOURNAL CODE: NYD. ISSN: 0470-8105., Japan *
RADIOLOGY, (1993 AUG) 188 (2) 347-50. JOURNAL CODE: QSH. ISSN: 0033-8419., United States *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279502B2 (en) 1999-04-30 2007-10-09 Cellgate, Inc. Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US7312244B2 (en) 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents

Also Published As

Publication number Publication date
EP1011737A2 (fr) 2000-06-28
WO1999013920A2 (fr) 1999-03-25
CA2301887A1 (fr) 1999-03-25
AU745908B2 (en) 2002-04-11
JP2001516730A (ja) 2001-10-02
AU1145999A (en) 1999-04-05

Similar Documents

Publication Publication Date Title
WO2001028491A3 (fr) Procede et composition utilises afin de traiter les affections dermatologiques
WO2002021993A3 (fr) Utilisation de rayonnements dans l'inhibition de l'hyperplasie suite a une intervention intravasculaire
HUP0104966A3 (en) A medical system and a method of controlling the system for use by a patient for medical self treatment
DE60028240D1 (de) Apparat und verfahren zur verabreichung einer asymmetrischen strahlungsdosis
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
WO1999062565A3 (fr) Dosimetrie selon patient
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
GB9727441D0 (en) Treatment of diseases
EP1555025A3 (fr) Utilisation d'analogues de déhydroépiandrostérone pour le traitement de l'asthme
FI960493A7 (fi) Menetelmä ja laite terapeuttiseen elektromagneettiseen hoitoon
FI964341A7 (fi) Prosessi ja laitteisto, joilla vähennetään kehon tietyissä kohdissa ol evaa rasvakudosta yhdistetyllä lämpökäsittelyllä ja lihastoiminnalla
GR3034508T3 (en) Use of insulin sensitizing agents to treat hypertension.
MX9302038A (es) Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
KR970704445A (ko) 페노티아진 및/또는 티옥산틴을 사용한 알츠하이머 병의 치료 및/또는 예방 방법(methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
CA2339384A1 (fr) Methode amelioree de traitement local cible de maladie
KR950700726A (ko) 치료 또는 진단용 조성물, 그 제조방법 및 용도(composition for therapeutic or diagnostic use, process for its preparation and its use)
WO1999013920A3 (fr) Methode pour le traitement curatif des affections proliferatives
WO2002056745A3 (fr) Methode de traitement de la maladie de parkinson
CA2282682A1 (fr) Traitement du psoriasis par le tazarotene et des corticoides
ITRM960364A0 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
WO2002087503A3 (fr) Compositions et methodes de traitement des polypes colorectaux et du cancer colorectal
WO2000006136A3 (fr) METHODE PERMETTANT DE TRAITER LE CANCER CHEZ DES PATIENTS PRESENTANT UNE DEFICIENCE DU SUPPRESSEUR DE TUMEUR p53
NO20014812L (no) Fremgangsmate for tilveiebringelse av kosmetisk/medisinsk terapi
TW353857B (en) Manufacturing method for bringing various parts of a body into a pattern and method for manufacturing a device thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998954267

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/000946

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2301887

Country of ref document: CA

Ref country code: CA

Ref document number: 2301887

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 11459/99

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09508972

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998954267

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 11459/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998954267

Country of ref document: EP